Jay Galeota, Kallyope CEO
February 27, 2025 06:11 AM ESTUpdated 06:25 AM
Startups
R&D

Kally­ope qui­et­ly re­ports Phase 2 obe­si­ty da­ta, be­gins mid-stage mi­graine tri­al

Kyle LaHucik

Senior Reporter

Elizabeth Cairns

Senior biopharma journalist

Kally­ope, a New York City biotech that has raised about $480 mil­lion over the past decade, qui­et­ly

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Can Bill An­der­son save Bay­er?

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Verve is lat­est gene edit­ing com­pa­ny to suf­fer set­back, as Ver­tex walks away from pact

Start­up work­ing on oral an­ti­bod­ies shares ear­ly ul­cer­a­tive col­i­tis da­ta

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times